Details

Autor(en) / Beteiligte

• Leon, Martin B
• Smith, Craig R
• Mack, Michael J
• Makkar, Raj R
• Svensson, Lars G
• Kodali, Susheel K
• Thourani, Vinod H
• Tuzcu, E. Murat
• Miller, D. Craig
• Herrmann, Howard C
• Doshi, Darshan
• Cohen, David J
• Pichard, Augusto D
• Kapadia, Samir
• Dewey, Todd
• Babaliaros, Vasilis
• Szeto, Wilson Y
• Williams, Mathew R
• Kereiakes, Dean
• Zajarias, Alan
• Greason, Kevin L
• Whisenant, Brian K
• Hodson, Robert W
• Moses, Jeffrey W
• Trento, Alfredo
• Brown, David L
• Fearon, William F
• Pibarot, Philippe
• Hahn, Rebecca T
• Jaber, Wael A
• Anderson, William N
• Alu, Maria C
• Webb, John G

Titel

Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients

Ist Teil von

• The New England journal of medicine, 2016-04, Vol.374 (17), p.1609-1620

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• In a randomized trial involving more than 2000 patients, transcatheter aortic-valve replacement was noninferior to surgical replacement in the primary end point of death from any cause or disabling stroke at 2 years. Transcatheter aortic-valve replacement (TAVR) is a new therapy for patients with severe aortic stenosis who are not candidates for surgery 1 , 2 or who are at high risk for complications due to surgery. 3 , 4 The acceptance of the use of TAVR in high-risk patients was based on evidence from clinical trials 5 , 6 that used early-generation TAVR devices; these procedures were associated with considerable procedure-related complications. 7 – 9 Recently, increased operator experience and enhanced transcatheter valve systems have led to a worldwide trend to use TAVR in patients who are at low or intermediate risk. 10 – 12 This trend has been evaluated in small . . .